Anne Leselbaum

Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million.

Part of Grifols SA, Gri-Cel SA provides investment services. The company is based in Barcelona, Spain. The CEO of the Spanish company is Dirk Büscher.

Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.

Vlaams Instituut voor Biotechnologie - Flanders Institute operates as a non-profit organization, provides research and development services. It specializes in translating basic scientific results into pharmaceutical, agricultural and industrial applications. The company was founded on January 1, 1996 and is headquartered in Ghent, Belgium.

THERAtRAME SA is a drug discovery start-up company based in Liege, Belgium. The Belgian company aims to become a leader in the development and positioning of novel cancer therapies by exploring new target areas to develop innovative cancer therapies. THERAtRAME's discovery platform integrates unique sets of technologies to discover, develop, and position new drugs to beat reluctant cancers. The company exploits the latest scientific discoveries highlighting the unexpected importance of trna epitranscriptomics dynamics in cancer. THERAtRAME is looking for a drug discovery assay developer leader to join their team. The company was founded by Francesca Rapino, Pierre Close, and has a team of experienced professionals with backgrounds in life sciences, medico-marketing, and biotech venture creations.

Bingli NV is a Belgian healthcare company that aims to free up 30%% of a doctor's time by reducing administrative burden and providing high-quality information for the right care at the right time. The company's mission is to put empathy back in healthcare by asking smart medical questions in advance, allowing doctors to be better prepared and appointments to be more time-efficient. The company is based in Antwerp, Belgium and was founded by Tom Van de Putte, Erica Cornu, Piet Van de Steen. Bingli's algorithms are used by more than 400,000 patients.

Noshaq SA is an independent private equity/venture capital firm founded in 1985. Noshaq SA is headquartered in Liege.

Sneezz BVBA helps individuals suffering from allergies such as hay fever by providing information and scientific insight. The private company is based in Borgloon, Belgium. Sneezz was founded in 2017 by Robert Jeroen Dekker, Marleen Johanna Limbourg, Peter Justin Georges Dedrij, Kristof Beenders, and Camiel Dobbelaar, with Robert Jeroen Dekker serving as CEO since 2017.

l'Associació Catalana d'Empreses de Biotecnologia is business association operating company. It is engaged in promoting health and life sciences activities for biotechnology organizations, business leaders, senior executives, entrepreneurs, investors and journalists. The company was founded in 2006 and is headquartered in Barcelona, Spain.

Founded in 1982, Aventis Pharma SARL is a French pharmaceutical company that manufactures pharmaceuticals. Part of Sanofi, the company is based in Antony, France.

Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products.

Nosopharm SAS operates as a biotechnology company. It develops an anti-infective drug platform that is based on the medicinal chemistry of a novel antibiotic class used to cure life-threatening multi-resistant hospital-acquired infections. The company was founded by Philippe Villain-Guillot and Maxime Gualtieri in February 2009 and is headquartered in Nimes, France.

Part of Sanofi, Aventis Pharma Ltd. is a British company that engages in the wholesale of pharmaceutical goods. The company is based in Reading, UK. Aventis Pharma was founded in 1980.

GlaxoSmithKline Consumer Healthcare manufactures and supplies over the counter drugs. It focuses on oral healthcare, over the counter medicines and nutritional healthcare products. Its brands and products include oral care (Aquafresh) to dermatology (Zovirax), with all kinds of analgesics (Panadol), gastrointestinal remedies (Tums) and smoking-cessation products (Nicoderm). The company is headquartered in Brentford, UK

Sanofi Pasteur SA develops, manufactures and supplies vaccines. It provides vaccines for bacterial and viral diseases, including diphtheria, typhoid fever, and poliomyelitis. The company was founded in 1990 and is headquartered in Lyon, France.

Part of Johnson & Johnson, Janssen Vaccines AG is a Swiss company that manufactures and distributes vaccines and immunotherapeutic products. The company is based in Bern, Switzerland.

AiCuris GmbH & Co. KG provides research and development services for antiviral and antibacterial agents. The firm develops drugs against viruses such as human cytomegalovirus, herpes simplex virus, hepatitis B virus and human immunodeficiency virus. The company was founded in March 2006 and is headquartered in Wuppertal, Germany.

Part of Aurora Optoelectronics Co., Ltd., GlaxoSmithKline Chongqing Co. Ltd. is a pharmaceutical company based in Chongqing, CN. GlaxoSmithKline Chongqing Co. was acquired by Aurora Optoelectronics Co., Ltd. from GSK Plc on December 31, 2004 for $12.81 million. The Chinese company manufactures pharmaceutical products.

Araclon Biotech SL researches and develops therapies and diagnostic methods for Alzheimer’s disease. Its research areas include early diagnosis of Alzheimer’s disease; therapy for Alzheimer’s disease; development of a predictive test for the Alzheimer’s disease in asymptomatic individuals; and development of therapy for Parkinson’s disease. The company was founded on January 27, 2004 and is headquartered in Zaragoza, Spain.